Federation Des Caisses Desjardins Du Quebec Nurix Therapeutics, Inc. Transaction History
Federation Des Caisses Desjardins Du Quebec
- $18.4 Billion
- Q4 2024
A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 290 shares of NRIX stock, worth $3,059. This represents 0.0% of its overall portfolio holdings.
Number of Shares
290
Previous 990
70.71%
Holding current value
$3,059
Previous $22,000
77.27%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding NRIX
# of Institutions
185Shares Held
67MCall Options Held
318KPut Options Held
42.4K-
Black Rock Inc. New York, NY6.82MShares$72 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.35MShares$45.8 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.19MShares$44.2 Million6.18% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$41 Million0.81% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.01MShares$31.7 Million0.01% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $497M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...